EdiGENE, a Tokyo, Japan based biotechnology company developing new CRISPR based therapies for treatment of genetic disorders, raised 1.6 Billion-yen (approx. $15M) as the first tranche of Series B round.
Participants included new investors UTokyo Innovation Platform along with continued support of existing investors including SBI Investment, Fast Track Initiative, SMBC Venture Capital, Mizuho Capital, CareNet Group.
The company intends to use the funds to extend its leadership position in gene modulation technology, and progress pipeline programs towards the clinic.
Led by Haru Morita, Chief Executive Officer, EdiGENE is a biotech company that develops therapeutics using its proprietary technology CRISPR-GNDM (Guide Nucleotide Directed Modulation). The company’s technology platform is capable of normalizing levels of gene expression without cutting the DNA or RNA.